BRPI0912219A2 - método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente. - Google Patents

método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente.

Info

Publication number
BRPI0912219A2
BRPI0912219A2 BRPI0912219A BRPI0912219A BRPI0912219A2 BR PI0912219 A2 BRPI0912219 A2 BR PI0912219A2 BR PI0912219 A BRPI0912219 A BR PI0912219A BR PI0912219 A BRPI0912219 A BR PI0912219A BR PI0912219 A2 BRPI0912219 A2 BR PI0912219A2
Authority
BR
Brazil
Prior art keywords
unit dose
dose form
opioid antagonist
orally administrable
peripherally acting
Prior art date
Application number
BRPI0912219A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan R Kugler
Kevin J Brodbeck
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of BRPI0912219A2 publication Critical patent/BRPI0912219A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0912219A 2008-05-07 2009-05-07 método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente. BRPI0912219A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07
PCT/US2009/002856 WO2009137086A1 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Publications (1)

Publication Number Publication Date
BRPI0912219A2 true BRPI0912219A2 (pt) 2015-10-06

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912219A BRPI0912219A2 (pt) 2008-05-07 2009-05-07 método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente.

Country Status (15)

Country Link
US (1) US20110160239A1 (enExample)
EP (1) EP2300009A1 (enExample)
JP (1) JP2011519930A (enExample)
KR (1) KR20110004425A (enExample)
CN (1) CN102014907A (enExample)
AU (1) AU2009244805B2 (enExample)
BR (1) BRPI0912219A2 (enExample)
CA (1) CA2723685C (enExample)
EA (1) EA201001643A1 (enExample)
IL (1) IL208794A0 (enExample)
MX (1) MX2010011727A (enExample)
MY (1) MY156913A (enExample)
NZ (1) NZ589733A (enExample)
WO (1) WO2009137086A1 (enExample)
ZA (1) ZA201007531B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TWI605814B (zh) * 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
SI2621496T2 (sl) * 2010-09-30 2019-04-30 Astrazeneca Ab Kristalinični konjugat naloksol-PEG
WO2013096444A1 (en) * 2011-12-19 2013-06-27 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015253417B2 (en) 2014-04-28 2020-02-20 Dimerx, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
WO2001032180A2 (en) * 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CN1925875A (zh) * 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
ES2629766T3 (es) * 2006-04-21 2017-08-14 Nektar Therapeutics Reducción estereoselectiva de una morfinona
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与

Also Published As

Publication number Publication date
KR20110004425A (ko) 2011-01-13
ZA201007531B (en) 2012-03-28
MY156913A (en) 2016-04-15
EA201001643A1 (ru) 2011-06-30
MX2010011727A (es) 2010-11-30
CA2723685C (en) 2016-09-27
WO2009137086A1 (en) 2009-11-12
NZ589733A (en) 2012-07-27
CN102014907A (zh) 2011-04-13
AU2009244805B2 (en) 2013-01-10
US20110160239A1 (en) 2011-06-30
AU2009244805A1 (en) 2009-11-12
JP2011519930A (ja) 2011-07-14
EP2300009A1 (en) 2011-03-30
CA2723685A1 (en) 2009-11-12
IL208794A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
FIC20253002I1 (fi) Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola
NO2022018I1 (no) Avacopan samt farmaceutisk acceptable salte deraf
NO2020034I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
NO2020039I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
CL2008000914A1 (es) Forma de dosificacion de liberacion modificada de tacrolimus.
DK1986650T3 (da) Manipulationssikre doserignsformer
BRPI1011414A2 (pt) "método."
FR2936709B1 (fr) Comprimes alcoolo-resistants.
IT1397291B1 (it) Dispositivo di rilevazione.
BRPI0912260A2 (pt) tonalizador.
EP2069930A4 (en) ADVANCED CONTENT DETECTION
DK3248978T3 (da) Deutererede morphinanforbindelser
BRPI0816422A2 (pt) compostos de cetal a partir de polióis e oxocarboxilatos.
BRPI0907382A2 (pt) Antagonista de receptor de opioide seletivo capa.
SMT201400113B (it) Nalmefene cloridrato diidrato
BRPI0925077A2 (pt) Conjunto dispensador.
BRPI1016190A2 (pt) compostos farmacêuticos.
BRPI1010021A2 (pt) mandril, e, combinação do mandril
DK2081689T3 (da) Valsemølle
BRPI0821291A2 (pt) Método, e, sistema
EP2197448A4 (en) dosing schedule
DK2252403T3 (da) Valsemølle
BRPI0807882A2 (pt) Forma de dosagem
DK2032260T3 (da) Rullemølle
BR112012004367A2 (pt) método de detecção de adulteração.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]